USPTO serial 86028683
KRINGLE PHARMA
Reviewed by CopyMark Law Group
Reg. 4545413Status 711
- Filing date
- Status date
- Registration date
- Jun 3, 2014
- Examiner
- CHUO, EMILY M
- Law office
- TMEG LAW OFFICE 101
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with KRINGLE PHARMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Sarah G. Voeller
Sarah G. Voeller HAMRE, SCHUMANN, MUELLER & LARSON, PC45 South Seventh Street, Suite 2700MINNEAPOLIS, MN 55402UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical, veterinary preparations for liver diseases, renal disease, nerve system diseases, skin diseases, cardiovascular diseases, cancer; Sanitary preparations for medical use; Central nervous system stimulants; Hair growth stimulant; Antipyretic analgesics; Anti-epileptics; Analeptics; Hypnotic sedatives; General anesthetics; Anti-motion sickness preparations; Pharmaceutical preparations acting on the peripheral nervous system; Local anesthetics; Skeletal muscle relaxants; Anhidrotics; Autonomics; Antispasmodics; Diaphoretics; Pharmaceutical preparations acting on the sensory organs; Ophthalmic preparations; Agents for otic and nasal use, namely, nasal spray preparations, eye washes, eye drops, irrigating solutions for eye use; Treatment for eye infection, macular degeneration, retinopathy, rhinitis, and sinusitis; Pharmaceutical antiallergic preparations; Antihistaminics; Cardiovascular treatment preparations; Cardiotonics; Antihypertensives; Vasoconstrictors; Capillary stabilizers; Cerebral hemorrhage prophylactic preparations; Antiarrhythmic preparations; Diuretics; Pharmaceutical preparations acting on respiratory organs; Respiratory stimulants; Anti-cough drops; Antitussive expectorants; Pharmaceutical preparations acting on digestive organs; Gastrointestinal cleaning agents; Clysters; Evacuants (purgatives); Stomachics and digestives; Pharmaceutical preparations for oral use, and for oral inflammation; Emetics; Pharmaceutical preparations for dental purposes for gingivostomatitis, alveolar abscess, and alveoloclasia; Antacids; Antiemetics; Castor oil for medical purposes; Cholagogues; Hormones for medical purposes; Thyroid and para-thyroid hormone preparations; Mixed hormone preparations; Estrogen preparations; Pancreas hormone preparations; Salivary gland hormone preparations; Androgen preparations; Pituitary hormone preparations; Adrenal hormone preparations; Pharmaceutical preparations acting on uro-genital and anal organs; Oxytocics; Anti-hemorrhoidals; Emmenagogues; Contraceptives; Medicated skin care preparations; Pharmaceutical preparations for purulence; Anti-dermoinfectives; Antimicrobials for dermatologic use; Astringents; Anti-inflammatory agents; Analgesics; Anti-itchings; Talcum powder for medical purposes; Medicated baby oils; Medicated baby powders; Medicated bath preparations; Vitamin preparations for medical purposes; Cod-liver oil drops for medical purposes; Mixed vitamin preparations for medical purposes; Vitamin A preparations for medical purposes; Vitamin C preparations for medical purposes; Vitamin D preparations for medical purposes; Vitamin B preparations for medical purposes; Multi-vitamin preparations for medical purposes; Amino acid preparations for medical purposes; Threonine preparations; Tryptophane preparations; Methionine preparations; Lysine preparations; Royal jelly for medical purposes; Calcium supplements for medical purposes; Chondroitin preparations for medical purposes; Protein and amino acid preparations for medical purposes; Saccharide preparations for treating skin diseases, namely, skin ulcer, injury, burn, scleroderma, dematitis, erythroderma, keratosis, dyschromatosis, and lupus erhthematosus; Mineral preparations for medical use; Anticoagulants; Blood substitutes for human and veterinary use; Blood plasma; Hemostatics; Pharmaceutical preparations affecting metabolism; Antidotes; Enzyme preparations for medical purposes; Lactagogues; Lipotropic factor preparations; Pharmaceutical preparations for the treatment of habitual intoxication; Pharmaceutical preparations for activating cellular function; Tumor suppressing agents; Anti-cancer preparations; Anti-sarcoma preparations; Pharmaceutical preparations for treating physically caused lesions; Pharmaceutical preparations for treating heatstroke; Radiation sickness treating drugs; Pharmaceutical preparations for treating chemically caused disorders, namely, chemical burn, side effect of anticancer drugs, and immunosuppresants; Chlorine-detoxication preparations; Arsenic-detoxication preparations; Benzol-detoxication preparations; Antibiotic preparations; Erythromycin preparations; Chloramphenicol preparations; Colistin-polymixin preparations; Sarkomycin preparations; Streptomycin preparations; Thiolutin preparations; Tetracycline preparations; Trichomycin preparations; Mixed antibiotic preparations; Penicillin preparations; Chemotherapeutics; Antisyphilitics; Antituberculous preparations; Sulfonamide preparations; Antileprotic preparations; Biological preparations for medical purposes; Antitoxic sera; Antitoxins; Mixed biological preparations for medical purposes; Preparations for biological tests for medical purposes; Toxoids; Vaccines; Preparations for destroying parasites; Anthelmintics; Odor neutralizing preparations for use on drugs; Pharmaceutical excipients; Diagnostic preparations for medical use; X-ray contrast agents; Diagnostic reagents for medical use; Diagnostic media for bacteriological cultures for medical use; Radio isotope markers for therapeutic or diagnostic use; Opium alkaloid preparations; Synthetic narcotics; Coca alkaloid preparations; Mosquito-repellent incenses; Germicides and fungicides; Rodenticides; Insecticides; Fumigants; Herbicides, namely, weedkillers; Insect-repellents; Antiseptics | SECTION 7(e) - CANCELLED | — |
| 042 | Testing, inspection or research of pharmaceuticals and genetics; Medical research; Consultancy and providing information services in the field of testing, inspection or research of pharmaceuticals and genetics; Consultancy and providing information services in the field of medical research; Providing medical and scientific research information and advice in the fields of pharmaceuticals and genetics | SECTION 7(e) - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 6, 2020 | NCS7 | NOTICE OF CANCELLATION SEC. 7 SURRENDER EMAILED | — |
| Jun 5, 2020 | C7.. | CANCELLED SECTION 7-TOTAL | — |
| Jun 4, 2020 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 30, 2020 | C7RF | REQUEST FOR SECT 7 TOTAL SURRENDER FILED | — |
| Apr 30, 2020 | ES7S | TEAS SECTION 7 SURRENDER RECEIVED | — |
| Apr 29, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 29, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 29, 2020 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Apr 29, 2020 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Apr 29, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 29, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 29, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jun 3, 2019 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jun 2, 2016 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 21, 2014 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Nov 21, 2014 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Nov 11, 2014 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Nov 11, 2014 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 3, 2014 | R.SR | REGISTERED-SUPPLEMENTAL REGISTER | Your mark is registered on the Supplemental Register, which is available for marks that are not yet distinctive enough for the Principal Register but can still identify a source. Protection is more limited than Principal Register registration but can later support a Principal Register application. |
| Apr 28, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Apr 25, 2014 | CNTA | APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER | — |
| Apr 24, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 24, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 14, 2014 | ALIE | ASSIGNED TO LIE | — |
| Apr 1, 2014 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 21, 2013 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 21, 2013 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 21, 2013 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 19, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 13, 2013 | MPMK | NOTICE OF PSEUDO MARK E-MAILED | — |
| Aug 12, 2013 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 8, 2013 | NWAP | NEW APPLICATION ENTERED | — |